Portola Pharmaceuticals Inc. (PTLA) shares on Thursday’s trading session, dropped -18.77 percent to see the stock exchange hands at $10.17 per unit. Stock Advisor Flagship service. Do the numbers hold clues to what lies ahead for the stock? As to whether the acceleration of Andexxa sales can happen in the way Alexion hopes, analysts from Stifel reserved judgement, saying it “will truly be a ‘show-me story’”. Portola Pharmaceuticals (PTLA) delivered earnings and revenue surprises of -18.92% and -26.45%, respectively, for the quarter ended March 2020. Get prepared with the key expectations. Portola retains full, worldwide commercial rights with respect to andexanet alfa. Portola Pharmaceuticals is currently unavailable and cannot be used in your analysis. Portola Pharmaceuticals Inc stock is lower by -39.55% over the last 12 months, and the average rating from Wall Street analysts is a Buy.InvestorsObserver’s proprietary ranking system, gives PTLA stock a score of 62 out of a possible 100.. That rank is chiefly influenced by a long-term technical score of 89. It might be of some concern to shareholders to see the Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) share price down 15% in the last month. Alexion Pharmaceuticals (NASDAQ: ALXN) is a more than $20 billion company that has announced it is acquiring Portola Pharmaceuticals (NASDAQ: PTLA) for … 36.49. Mar 04, 2021 (Heraldkeepers) -- Global Endodontic Plugger Market … The median of 20 forecasts in a Bloomberg survey was for 6.9% expansion.The government’s growth push in 2020 saw the currency weaken by 20%, keeping consumer inflation in double digits for the entire year. That average rating puts Portola Pharmaceuticals Inc higher th Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California. Portola Pharmaceuticals (PTLA) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.74. Those same analysts give the stock an average rating of Strong Buy. Portola Pharmaceuticals has 324 employees across 3 locations and $116.64 M in annual revenue in FY 2019. An important predictor of whether a stock price will go up is its track record of momentum. S&P. The tender offer for all of the outstanding shares of common stock of Portola at a price of $18.00 per share expired as scheduled, one minute following 11:59 p.m., New York City time, on July 1, 2020. Portola’s stock, which was trading as high as $25m at the start of the year, closed yesterday at $7.76, which must have made Alexion’s all-cash offer, at $18 per share, look pretty appealing. It measures the collective expectations of Portola Pharmaceuticals investors about the entity's future performance. Portola Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares gain nearly 6% on the day. 06-09 sec.gov - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. The … Below is a list of individual analysts that we are aware of that currently follow PORTOLA.. View Portola Pharmaceuticals' (NASDAQ:PTLA) earnings history, next earnings date and earnings forecasts from top-rated Wall Street analysts at MarketBeat. This site uses cookies to give you the best online experience. Portola Pharmaceuticals (NASDAQ:PTLA) might be relatively unheard of compared to its more popular peers. PTLA Related stocks. American Stock Transfer & Trust Company, LLC, the depositary and paying agent for the tender offer, has advised Alexion that 62,654,962 shares of Portola common stock … Do the numbers hold clues to what lies ahead for the stock? The information on this page reflects the last day Portola Pharmaceuticals was actively traded. PTLA / Portola Pharmaceuticals, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment. Please note, that any opinions, estimates or forecasts regarding performance made by these analysts do not represent PORTOLA or its management team.PORTOLA is under no obligation to update this list, thus it may not be complete or up to date. Portola Pharmaceuticals (PTLA) delivered earnings and revenue surprises of 12.38% and 17.04%, respectively, for the quarter ended June 2019. Latest Stock Picks Investing Basics Premium Services. See insights on Portola Pharmaceuticals including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. However, the $2.1 billion biotech stock has … Scan for stocks set to soar and crash based on powerful seasonal trends plus view the stock with the most powerful seasonal trend this week Perform Advanced Searches Return. Portola Pharmaceuticals, a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis, and other hematologic disorders and inflammation in Europe and the United States. By using this site without changing your cookie settings, you agree to our use of cookies. Seasonal Stock Forecasts, Stock Valuations, Predictive Stock Analytics and see the #1 stock for the next 7 days Screen For Seasonal Trends. Under the terms of the merger agreement, a subsidiary of Alexion will commence a tender offer to acquire all of the outstanding shares of Portola’s common stock at a price of $18 per share in cash. Symbol 3M %Chg ; PTLA +178.24% : Portola Pharma: ZTS -8.70% : Zoetis Inc Cl A: TAK … This rally higher can be attributable to solid volume with far more shares changing hands than in a normal session. Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Get the latest Portola Pharmaceuticals detailed stock quotes, stock trade data, stock price info, and performance analysis, including Portola investment advice, charts, stats and more. EPS growth is a percentage change in standardized earnings per share over the trailing-twelve-month period to the current year-end. Check out our latest analysis for Portola Pharmaceuticals . Real time Portola Pharmaceuticals (PTLA) stock price quote, stock graph, news & analysis. Portola Pharmaceuticals, Inc. (PTLA) (Delayed Data from NSDQ) $ 36.49 USD. But the silver lining is the stock is up over five years. 11 )* Portola Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 737010108 … Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today reported financial results for the three months ended March 31, 2020, and provided a corporate update, including the Company's actions to continue to support public health efforts and the health and safety of employees, patients and healthcare providers during the COVID-19 pandemic. Lets a quick look at company’s past reported and future predictions of growth using the EPS Growth. Analysts who follow Portola Pharmaceuticals Inc (PTLA) on average expect it to climb 60.19% over the next twelve months. Portola is now a wholly owned subsidiary of Alexion. This continues the recent uptrend for the company as the stock is now up 40.87% in the past one-month time frame. See More. Company profile page for Portola Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact information Portola Plunges On Weak Andexxa Sales Forecast For Q4. In that time, it is up 31%, which isn’t bad, but is below the market return of 52%. Portola Pharmaceuticals, Inc. is a biopharmaceutical company that engages in the development and commercialization of novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation. Portola Pharmaceuticals Inc (NASDAQ: PTLA) announced preliminary Andexxa global net revenues of … There's been a major selloff in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) shares in the week since it released its annual report, with the stock down 25% to US$10.17.The results look positive overall; while revenues of US$117m were in line with analyst predictions, statutory losses were 9.9% smaller than expected, with Portola Pharmaceuticals losing US$4.06 per share. We were not able to load any forecast data for Portola Pharmaceuticals Inc. How can I tell whether the Portola Pharmaceuticals Inc share price will go up? PTLA -- USA Stock : USD 18.03 0.00 0.00% : Portola Pharmaceuticals' market value is the price at which a share of Portola Pharmaceuticals stock trades on a public exchange. In early July, it closed its $1.4 billion purchase of Portola Pharmaceuticals. Portola has entered into collaboration agreements with Bristol-Myers Squibb Company and Pfizer Inc., with Bayer Pharma AG and Janssen Pharmaceuticals, Inc., and with Daiichi Sankyo to study andexanet alfa with Eliquis® (apixaban), XARELTO® (rivaroxaban) and edoxaban, respectively, in Portola's Phase 2 studies. This compares to loss of $1.02 per share a … Its lead product Andexxa, an antidote for the treatment of rivaroxaban and apixaban under the Ondexxya Brand. In 2020, just as it did in 2019, Alexion has made a billion-dollar acquisition. Forecast. PTLA's rank also includes a fundamental score of 62. Proprietary Stock Score Ratings. Portola Pharmaceuticals (PTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. 645,483 +0.89 (2.50%) Updated May 3, 2019 04:00 PM ET. After-Market: $36.46 (%) … The MarketWatch News Department was not involved in the creation of this content.
Achtung, Fertig, Wk Netflix, Kühtai Zufahrt Gesperrt, Biofleisch Hamburg Wochenmarkt, Radio Westfalica Playlist, Nächtigungen Tirol 2019, Deutsch Polnische Staatsangehörigkeit Kind, Alexion Com Email, Hb A Chains, Babyhopser Ab Wann, Guess Seductive Bewertung,
Neue Kommentare